Antiepileptische Therapie

  • Kazimierz Karbowski

Zusammenfassung

Der Entscheid darüber, ob und gegebenenfalls wie ein Patient mit epilepsieverdôchtige Anfällen behandelt werden soll, wird erst dann gefaßt, wenn der Arzt die im Kapitel II erwähnten diagnostischen Probleme gelöst hat. Dabei ist folgendes zu berücksichtigen

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu Kapitel VIII

  1. 1.
    Agarwal BN, Cabebe FG, Hoffmann BJ (1977) Diphenylhydantoin - induced acute renal failure. Nephron 18:249–251PubMedCrossRefGoogle Scholar
  2. 2.
    Albert J, Waldburger M (1983) Forme chronique D’algoneurodystrophie secondaire au traitement de phénobarbital. Rev med (Praxis) 24:1679–1682Google Scholar
  3. 3.
    Arbeitsgruppe für das AFP-Screening in der Schweiz (1985) Früherfassung kindlicher Miß-bildungen des Rückenmarkes und des Gehirns: Das AFP-Screening - Ergebnisse einer Studie bei 16000 schwangeren Frauen in der Schweiz. Schweiz Aerzte Ztg 66:274–284Google Scholar
  4. 4.
    Asconapé JJ, Penry JK (1982) Use of antiepileptic drugs in the presence of liver and kidney disease: A review. Epilepsia 23 (Suppl 1) 65–79CrossRefGoogle Scholar
  5. 5.
    Back DJ, Bates M, Bowden A, Breckenridge AM, Hall MJ, Jones H, Maclever M, Orme M, Perucca E, Richens A, Rowe PH, Smith E (1980) The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 22:495–503PubMedCrossRefGoogle Scholar
  6. 6.
    Ballenger CE, Lucke JF, King DW, Gammal TE, Brooks BS, Green JB (1982) Cerebellar atrophy in epilepsy and headache: Lack of relationship to phenytoin. Neurology 32:910– 912PubMedGoogle Scholar
  7. 7.
    Bar S, Feller N, Savir H (1983) Presenil cataracts in phenytoin-treated epileptic patients. Arch Ophthalmol 101:422–425PubMedCrossRefGoogle Scholar
  8. 8.
    Battino D, Avanzini G, Bossi L, Canger R, Como ML, Croci D, Spina S (1982) Monitoring of antiepileptic drugs plasma levels during pregnancy and puerperium. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 147–154. Raven Press, New YorkGoogle Scholar
  9. 9.
    Battino D, Binelli S, Bossi L, Como ML, Croci D, Cusi C, Avanzini G (1984) Changes in primidone/phenobarbitone ratio during pregnancy and the puerperium. Clin Pharmacokin 9:252–260CrossRefGoogle Scholar
  10. 10.
    Beck-Mannagetta G, Drees B, Janz D (1982) Malformations and minor anomalies in the offspring of epileptic parents: a retrospective study. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 317–323. Raven Press, New YorkGoogle Scholar
  11. 11.
    Bickerstaff ER (1975) Neurological complications of oral contraceptives. Clarendon Press, OxfordGoogle Scholar
  12. 12.
    Bing R (1940) Lehrbuch der Nervenkrankheiten. 6. Auflage, p. 585–588. Schwabe, BaselGoogle Scholar
  13. 13.
    Bjerkedal T, Czeizel A, Goujard J, Kallen B, Mastroiacova P, Nevin N, Oakley G, Robert E (1982) Valproic acid and spina bifida. Lancet II/1096 u. 1172CrossRefGoogle Scholar
  14. 14.
    Blom S (1962) Trigeminal neuralgia: Its treatment with a new anticonvulsant drug (G-32883). Lancet 1/839–840PubMedCrossRefGoogle Scholar
  15. 15.
    Boenigk HE, Lorenz JH, Jürgens U (1984) Aktuelle Erfahrungen mit Bromiden zur Behandlung generalisierter Epilepsien. 25. Jubiläumstagung der Deutschen Sektion der Intern. Liga gegen Epilepsie in Kehl. Zusammenfassungen der Referate, S 139Google Scholar
  16. 16.
    Bonduelle M, Bouygues P, Sallou C, Chemaly R (1964) Bilan de 1’expérimentation clinique de 1’anti-épileptique G 32883 [5-Carbamoyl-5-H-dibenzo-(b, f) azépine]. Résultats de 89 observations. In: Bradley PB, Flügel F, Hock PH (eds) Proc. ITI Congr. Intern. Neuro-Psy-chopharmac. München 1962, Vol. 3, p. 312–315. Elsevier, AmsterdamGoogle Scholar
  17. 17.
    Bonkowsky HL (1981) Carbamazepine in seizure management in acute intermittent porphyria. Reply from the author. Neurology 31:1579Google Scholar
  18. 18.
    Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF (1980) Seizure management in acute hepatic porphyria: Risks of valproate and clonazepam. Neurology 30:588–592PubMedGoogle Scholar
  19. 19.
    Bonkowsky HL, Shedlofsky SI, Sinclair PR (1982) Seizure management and hepatic porphyrias. Reply from the authors. Neurology 32:1410Google Scholar
  20. 20.
    Booker HE (1972) Primidone. Relation of plasma levels to clinical control. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 373–376. Raven Press, New YorkGoogle Scholar
  21. 21.
    Booker HE (1972) Primidone. Toxicity. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 377–383. Raven Press, New YorkGoogle Scholar
  22. 22.
    Bossi L (1982) Neonatal period including drug disposition in newborns: Review of literature. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 327–341. Raven Press, New YorkGoogle Scholar
  23. 23.
    Browning RA, Maynert EW (1972) Phenobarbital, mephobarbital and metharbital. Toxicity. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 345–351. Raven Press, New YorkGoogle Scholar
  24. 24.
    Buchanan RA (1972) Ethosuximide. Toxicity. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepiletic Drugs, p. 449–454. Raven Press, New YorkGoogle Scholar
  25. 25.
    Burgess ED, Friel PN, Blair AD, Raisy VA (1981) Serum phenytoin concentrations in uremia. Ann Intern Med 94:59–60PubMedGoogle Scholar
  26. 26.
    Calmeil LF (1824) De l’épilepsie, étudiée sous le rapport de son siège et de son influence sur la production de l’aliénation mentale. These. Didot le jeune, ParisGoogle Scholar
  27. 27.
    Chadwick D, Reynolds EH, Marsden CD (1976) Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol, Neurosurg, Psychiatr 39:1210–1218CrossRefGoogle Scholar
  28. 28.
    Chadwick D, Shaw MDM, Foy P, Rawlins MD, Turnbull DM (1984) Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. Neurol Neurosurg Psychiat 47:642–644CrossRefGoogle Scholar
  29. 29.
    Chalk JB, Ridgeway K, Brophy T, Yelland JDN, Eadie MJ (1984) Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol, Neurosurg, Psychiat 47:1087–1090CrossRefGoogle Scholar
  30. 30.
    Chapman A, Keane PE, Meldrum BS, Simiand J, Vernieres JC (1982) Mechanisms of anticonvulsant action of valproate. Progr Neurobiol 19:315–359CrossRefGoogle Scholar
  31. 31.
    Christiansen C, Rodbro P, Tjellesen L (1983) Pathophysiology behind anticonvulsant osteomalacia. Acta Neurol Scand 67, Suppl 94:21–28Google Scholar
  32. 32.
    Cleland P (1983) The female with epilepsy: pros and cons of anticonvulsant therapy. In: Jeavons PM, Anfield L (eds) Third International Symposium on Sodium Valproate. Br J Clin Pract, Symp Suppl 27:42–47Google Scholar
  33. 33.
    Clifford DB (1984) Seizures and pregnancy. Am Fam Physician 29:271–275PubMedGoogle Scholar
  34. 34.
    Committee on Drugs (1982) Valproic acid: Benefits and risks. Pediatrics 70:316–318Google Scholar
  35. 35.
    Coulam CB, Annegers JF (1979) Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 20:519–526PubMedCrossRefGoogle Scholar
  36. 36.
    Coulter DL, Allen RJ (1979) Pancreatitis associated with valproic acid therapy for Epilepsy. Ann Neurol 7:92CrossRefGoogle Scholar
  37. 37.
    Dam M (1972) Diphenylhydantoin. Neurologic Aspects of Toxicity. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 227–235. Raven Press, New YorkGoogle Scholar
  38. 38.
    Dam M, Dam AM (1984) Epilepsie et grossesse. Epilepsie-Informationsblatt der Schweizerischen Liga gegen Epilepsie 4:2–11Google Scholar
  39. 39.
    Danner R (1983) Nebenwirkungen von Phenytoin und Carbamazepin auf elektrophysiologische Funktionen des peripheren Nervensystems. Nervenarzt 54:530–534PubMedGoogle Scholar
  40. 40.
    Dansky L, Andermann E, Shervin AL, Andermann F (1982) Plasma levels of phenytoin during pregnancy and puerperium. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 155–162. Raven Press, New YorkGoogle Scholar
  41. 41.
    Dayer P (1982) Einige klinische Untersuchungen zur Behandlung von Patienten mit Niereninsuffizienz. Sandorama 1:40–42Google Scholar
  42. 42.
    Deisenhammer E, Schwarzbach H, Sommer R (1982) Erhöhung der Gamma-GT bei antikonvulsiver Therapie. Wien klin Wschr 94:584–585PubMedGoogle Scholar
  43. 43.
    Delgado-Escueta AV, Wasterlan C, Treiman DM, Porter RJ (1982) Current concepts in neurology: Management of status epilepticus. N Engl J Med 306:1337–1340PubMedCrossRefGoogle Scholar
  44. 44.
    Delgado-Escueta AV, Treiman DM, Walsh GO (1983) The treatable epilepsies. Second of two parts (1983) N Engl J Med 308:1576–1584PubMedCrossRefGoogle Scholar
  45. 45.
    Dutton P (1958) Phenytoin toxicity with associated meningeal reaction. J Ment Sci 104:1165–1166PubMedGoogle Scholar
  46. 46.
    Editorial (1982) Valproate and malformations. Lancet 11/1313–1314Google Scholar
  47. 47.
    Egenaes J (1982) Outcome of pregnancy in women with epilepsy - Norway, 1967 to 1978: Complications during pregnancy and delivery. In: Janz D et al (eds) Epilepsie, Pregnancy and the Child, p. 81–90. Raven Press, New YorkGoogle Scholar
  48. 48.
    Egerton Vernon JM, Fisk MJ, Snell AP (1983) Phenytoin-induced hepatotoxity. N Z Med J 96:467–469PubMedGoogle Scholar
  49. 49.
    Encinoza O (1974) Nerve conduction velocity in patients on long-term diphenylhydantoin therapy. Epilepsia 15:147–154PubMedCrossRefGoogle Scholar
  50. 50.
    Fabro S, Brown NA (1979) Teratogenic potential of anticonvulsants. N Engl J Med 300:1280–1281PubMedGoogle Scholar
  51. 51.
    Fedrick J (1973) Epilepsy and pregnancy: A report from Oxford record linkage study. Br Med J 2:442–448PubMedCrossRefGoogle Scholar
  52. 52.
    Ferrendelli JA, Kupferberg HJ (1980) Antiepileptic Drugs. Succinimides. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol 27:587–596. Raven Press, New YorkGoogle Scholar
  53. 53.
    Fincham RW, Schottelius DD, Sahs AL (1974) The influence of diphenylhydantoin on primidone metabolism. Arch Neurol (Chicago) 30:259–262CrossRefGoogle Scholar
  54. 54.
    Finnell RJ, Chernoff GF (1984) Editorial comment: Genetic background: The elusive component in the fetal hydantoin syndrome. Am J Medic Genet 19:459–162CrossRefGoogle Scholar
  55. 55.
    Finnell RJ, Chernoff GF (1984) Variable patterns of malformation in the mouse fetal hydantoin syndrome. Am J Medic Genet 19:463–471CrossRefGoogle Scholar
  56. 56.
    Friis ML (1983) Antiepileptic drugs and teratogenesis. How should patients, doctors and authorities be counselled? Acta Neurol Scand 67, Suppl 94:39–43Google Scholar
  57. 57.
    Fröscher W (1976) Therapie des Status epilepticus. Schattauer, Stuttgart New YorkGoogle Scholar
  58. 58.
    Fröscher W, Hoffmann F (1983) Dupuytrensche Kontraktur und Phenobarbitaleinnahme bei Epilepsie-Patienten. Nervenarzt 54:413–419PubMedGoogle Scholar
  59. 59.
    Fuchs T, Seubert A, Seubert S, Ippen H (1980) Anticonvulsant-induced unclassified porphyria. Int J Biochem 12:955–957PubMedCrossRefGoogle Scholar
  60. 60.
    Gallagher BB, Baumel IP (1972) Primidone. Absorption, distribution, and excretion. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 357–359. Raven Press, New YorkGoogle Scholar
  61. 61.
    Gallagher BB, Baumel IP (1972) Primidone. Biotransformation. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 361–366. Raven Press, New YorkGoogle Scholar
  62. 62.
    Gambertoglio JG, Lauer RM (1981) Use of neuropsychiatric drugs. In: Anderson RJ, Schreier RW (eds) Clinical Use of Drugs in Patient with Kidney and Liver Disease, p. 276– 295. Saunders, Philadelphia-London-Toronto-SydneyGoogle Scholar
  63. 63.
    Gancher S, Laxer KD, Krieger W (1984) Activation of epileptogenic activity by etomidate. Anesthesiology 61:616–618PubMedCrossRefGoogle Scholar
  64. 64.
    Gastaut H (1976) Wörterbuch der Epilepsie. Deutsche Übersetzung und Bearbeitung von J. Kugler. Hippokrates, StuttgartGoogle Scholar
  65. 65.
    Gates JR, Leppik IE, Yap J, Gumnit RJ (1984) Corpus callosotomy: Clinical and electroencephalographic effects. Epilepsia 25:308–316PubMedCrossRefGoogle Scholar
  66. 66.
    Geraldini C, Faedda MT, Sideri G (1984) Anticonvulsant therapy and its possible consequences on peripheral nervous system: A neurographic study. Epilepsia 25:502–505PubMedCrossRefGoogle Scholar
  67. 67.
    German I, Kowal A, Ehlers KH (1970) Trimethadione and human teratogenesis. Teratology 3:349–361PubMedCrossRefGoogle Scholar
  68. 68.
    Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL (1983) Anticonvulsant-induced aplastic anemia: Increased susceptibility to toxic drug metabolites in vitro. Blood 61:889– 893PubMedGoogle Scholar
  69. 69.
    Glaser GH (1972) Diphenylhydantoin. Toxicity. In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 219–226. Raven Press, New YorkGoogle Scholar
  70. 70.
    Goldberg MA (1980) Phenytoin: Binding. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol.27: p. 323–337. Raven Press, New YorkGoogle Scholar
  71. 71.
    Goldberg MA (1980) Phenobarbital: Binding. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol. 27: p. 501– 504. Raven Press, New YorkGoogle Scholar
  72. 72.
    Goldring JM, Blaustein MP (1980) Barbiturates: Physiological effects II. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol. 27: p. 523–531. Raven Press, New YorkGoogle Scholar
  73. 73.
    Gram L, Bentsen KD (1984) Controlled and comparative trials of valproate performed in Europa and Asia. Epilepsia 25 (Suppl 1):32–39CrossRefGoogle Scholar
  74. 74.
    Halama P (1984) Chronische Hepatopathien durch Antikonvulsiva. Die therapeutische Wirkung von Silymarin. Therapiewoche 34:2267–2274Google Scholar
  75. 75.
    Hamilton DV (1978) Carbamazepine and heart block. Lancet I/1365CrossRefGoogle Scholar
  76. 76.
    Handley R, Stewart ASR (1952) Mysoline: A new drug in the treatment of epilepsy. Lancet I/742–744CrossRefGoogle Scholar
  77. 77.
    Hansen JM, Siersbaek-Nielsen K, Kristensen M, Skovsted L, Christensen LK (1971) Effect of diphenylhydantoin on the metabolism of dicoumarol in man. Acta med Scand 189:15– 19PubMedCrossRefGoogle Scholar
  78. 78.
    Hassell T, O’Donnell J, Pearlman J, Tesini D, Murphy T, Best H (1984) Phenytoin induced gingival overgrowth in institutionalized epileptics. J clin Periodontol II:242–253CrossRefGoogle Scholar
  79. 79.
    Hauptmann A (1912) Luminal bei Epilepsie. Münch med Wschr 69:1907–1909Google Scholar
  80. 80.
    Herzberg L (1978) Carbamazepine and bradycardia. Lancet I/1097–1098CrossRefGoogle Scholar
  81. 81.
    Hess B, Keusch G, Fluckiger J, Binswanger U (1984) Zur Pharmakokinetik von Phenytoin bei kontinuierlicher ambulanter Peritonealdialyse. 2 Fôlle und kurze Literaturübersicht. Schweiz Med Wschr 114:16–19PubMedGoogle Scholar
  82. 82.
    Hess CW (1980) Das Carbamazepin. Schweiz Rundschau Med (Praxis) 69:803–808Google Scholar
  83. 83.
    Hiilesmaa VK (1983) Evaluation of placental function in women on antiepileptic drugs. Perinat Med 11:187–192CrossRefGoogle Scholar
  84. 84.
    Hill RM (1982) The advisability of increasing antiepileptic drug dosage during pregnancy. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 163. Raven Press, New YorkGoogle Scholar
  85. 85.
    Höglmeier H, Wenzel U (1969) Zerebellarer Dauerschaden durch vorübergehende Hydantoinüberdosierung. Dtsch med Wschr 94:1330–1332PubMedCrossRefGoogle Scholar
  86. 86.
    Holm E, Kelleter R, Heinemann H, Hamann KF (1970) Elektrophysiologische Analyse der Wirkung von Carbamazepin auf das Gehirn der Katze. Pharmakopsychiat Neurol Psychopharmakol 3:187–200Google Scholar
  87. 87.
    Hruby K, Lenz K, Druml W, Kleinberger G (1982) Erfahrungen mit akuten Vergiftungen durch Carbamazepin. Nervenarzt 53:414–418PubMedGoogle Scholar
  88. 88.
    Hüter J (1970) Übergang von Medikamenten in die Muttermilch und Nebenwirkungen beim gestillten Kind, S.29. Thieme, StuttgartGoogle Scholar
  89. 89.
    Iivanainen M, Savolainen H (1983) Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy. Acta Neurol Scand 68, Suppl 97:49–67CrossRefGoogle Scholar
  90. 90.
    James MFM, Manson EDM (1985) The use of magnesium sulphate infusions in the management of very severe tetanus. Intensive Care Med 11:5–12PubMedCrossRefGoogle Scholar
  91. 91.
    Janz D (1969) Die Epilepsien. Thieme, StuttgartGoogle Scholar
  92. 92.
    Janz D (1982) Antiepileptic drugs and pregnancy: Altered utilization pattern and teratogenesis. Epilepsia 23 (Suppl. 1):53–63CrossRefGoogle Scholar
  93. 93.
    Janz D, Schmidt D (1974) Anti-epileptic drugs and failure of oral contraceptives. Lancet I/1113CrossRefGoogle Scholar
  94. 94.
    Jeavons PM (1984) Non-dose-related side effects of valproate. Epilepsia 25 (Suppl. 1):50– 55CrossRefGoogle Scholar
  95. 95.
    Jensen I (1975) Temporal lobe surgery around the world. Acta Neurol Scand 52:354–373PubMedCrossRefGoogle Scholar
  96. 96.
    Johnston D (1984) Valproic acid: Update on its mechanisms of action. Epilepsia 25 (Suppl. 1):1–4CrossRefGoogle Scholar
  97. 97.
    Karbowski K (1976) Der Petit mal-Status. Schweiz med Wschr 106:973–981PubMedGoogle Scholar
  98. 98.
    Karbowski K, Wegmüller E (1983) Epileptische Anfälle und Myoklonien bei Niereninsuffizienz. Schweiz Rundschau Med (Praxis) 72:832–839Google Scholar
  99. 99.
    Kaspar U (1980) Das Diphenylhydantoin. Schweiz Rundschau Med (Praxis) 69:795–802Google Scholar
  100. 100.
    Klotz U, Rapp T, Müller WA (1978) Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 13:55–60PubMedCrossRefGoogle Scholar
  101. 101.
    Knoche E, Traub E, Schuhmann RA (1983) Sofortmaßnahmen bei schwerer Präeklampsie und eklamptischem Anfall. Notfallmedizin 9:1178–1192Google Scholar
  102. 102.
    Koch S, Göpfert-Geyer I, Jäger-Roman E, Jakob S, Huth H, Hartmann A, Rating D, Helge H (1983) Antiepileptika während der Schwangerschaft. Eine prospektive Studie über Schwangerschaftsverlauf, Fehlbildungen und kindliche Entwicklung. Dtsch med Wschr 108:250–257PubMedCrossRefGoogle Scholar
  103. 103.
    Kohl PK (1978) Das Mißbildungsrisiko der antiepileptischen Therapie. Deutsche Sektion der Intern. Liga gegen Epilepsie. Rundbrief 61:31–32Google Scholar
  104. 104.
    Körner E, Ladurner G, Enge S, Lechner H (1983) Hydantoinintoxikation: Klinik, Labor und EEG. Nervenarzt 54:548–552PubMedGoogle Scholar
  105. 105.
    Kruse R (1977) Ambulante Epilepsiebehandlung. Wichtige Gesichtspunkte für die Durchführung einer medikamentösen Langzeittherapie in der Praxis. Schweiz Rundschau Med (Praxis) 66:1359–1371Google Scholar
  106. 106.
    Kruse R (1982) Rektale und parenterale Ersatzmedikation der antiepileptischen Langzeittherapie bei Operationen in Allgemeinanästhesie. In: Opitz A, Degen R, Kugler J (Hrsg) Anästhesie bei Epileptikern und Behandlung des Status epilepticus, p. 65–88. Editiones „Roche“Google Scholar
  107. 107.
    Kutt H (1984) Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 25 (Suppl 2): 118–131CrossRefGoogle Scholar
  108. 108.
    Kutt H, Winters W, Scherman R, McDowell F (1964) Diphenylhydantoin and phenobarbital toxicity. The role of liver disease. Arch Neurol 11:649–656PubMedCrossRefGoogle Scholar
  109. 109.
    Kutt H, Solomon GE (1980) Antiepileptic Drugs. Phenytoin: Relevant side effects. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action, p. 435–445. Raven Press, New YorkGoogle Scholar
  110. 110.
    Ladefoged SD, Mogelvang JC (1982) Total atrioventrikular block with syncopes complicating carbamazepine therapy. Acta Med Scand 212:185–186PubMedCrossRefGoogle Scholar
  111. 111.
    Lankisch PG (1980) Akute Pankreatitis unter antikonvulsiver Therapie mit Natrium valproat (Ergenyl). Dtsch med Wschr 105:905PubMedGoogle Scholar
  112. 112.
    Larson AW, Wasserstrom WR, Felsher BF, Shih JC (1978) Posttraumatic epilepsy and acute intermittent porphyria: Effects of phenytoin, carbamazepine and clonazepam. Neurology 28:824–828PubMedGoogle Scholar
  113. 113.
    Laxer KD, Robertson LT, Julien RM, Dow RS (1980) Phenytoin: Relationship between cerebellar function and epileptic discharges. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol 27: p. 415–427. Raven Press, New YorkGoogle Scholar
  114. 114.
    Letteri JM, Mellk H, Louis S, Kitt H, Durante P, Glazko A (1971) Diphenylhydantoin metabolism in uremia. N Engl J Med 285:648–652PubMedCrossRefGoogle Scholar
  115. 115.
    Levitan Z, Samberg I, Peled R, Sharf M (1983) Fetal heart rat during maternal grand mal epileptic seizures. J Foetal Med 3:59–62Google Scholar
  116. 116.
    Levy RH (1984) Variability in level-dose ratio of valproate: Monotherapy versus polytherapy. Epilepsia 25 (Suppl. 1): 10–13CrossRefGoogle Scholar
  117. 117.
    Levy RH, Moreland TA (1984) Clinical pharmacokinetics of sodium-valproate, carbamazepine and phenytoin. Schweiz Rundschau Med (Praxis) 73:159–163Google Scholar
  118. 118.
    Lindhout D, Höppener RJEA, Meinardi H (1984) Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of Carbamazepine). Epilepsy 25:77– 83CrossRefGoogle Scholar
  119. 119.
    Liponi DF, Winter ME, Tozer TN (1984) Renal function and therapeutic concentrations of phenytoin. Neurology 34:395–397PubMedGoogle Scholar
  120. 120.
    Livingston S (1972) Comprehensive management of epilepsy in infancy, childhood and adolescence. Thomas, Springfield-IllinoisGoogle Scholar
  121. 121.
    Livingston S, Petersen D, Boks LL (1955) Hypertrichosis occuring in association with Dilantin therapy. J Pediatr 47:351–352PubMedCrossRefGoogle Scholar
  122. 122.
    Loiseau P (1984) Rational us of Valproate: Indications and drug regimen in epilepsy. Epilepsia 25 (Suppl l):65–72CrossRefGoogle Scholar
  123. 123.
    Lorgé M (1963) Klinische Erfahrungen mit einem neuen Antiepilepticum, Tegretol (G 32883), mit besonderer Wirkung auf die epileptische Wesensveränderung. Schweiz med Wschr 93:1042–1047Google Scholar
  124. 124.
    Lorgé M (1964) Über ein neuartiges Antiepileptikum der Iminostilbenreihe (G 32883). In: Bradley PB, Flügel F, Hock PH (eds) Proc. III Congr. Intern. Neuro-Psychopharmac. München 1962, Vol.3, p.299–302. Elsevier, AmsterdamGoogle Scholar
  125. 125.
    Magnussen CR, Doherty JM, Hess RA, Tschudy DP (1975) Grand mal seizures and acute intermittent porphyria. Neurology 25:1121–1125Google Scholar
  126. 126.
    Majewski F, Raff W, Fischer P, Huenges R, Petruck F (1980) Zur Teratogenität von Antikonvulsiva. Dtsch med Wschr 105:719–723PubMedCrossRefGoogle Scholar
  127. 127.
    Majewski F, Steger M, Richter B, Gill J, Rabe F (1981) The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Int J Biol Res Pregnancy 2:37–45PubMedGoogle Scholar
  128. 128.
    Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH (1972) Effect of diphenylhydantoin on insulin secretion in man. N Engl J Med 286:339–342PubMedCrossRefGoogle Scholar
  129. 129.
    Mattson RH, Cramer JA (1980) Valproic and ethosuximide interaction. Ann Neurol 7:583– 584PubMedCrossRefGoogle Scholar
  130. 130.
    Mauguière F, Courjon J (1983) Les effect secondaires des médicaments antiépileptiques (données recentes). Lyon méd 249:193–198Google Scholar
  131. 131.
    Maxwell JD (1976) Enzyme induction and drug sensitivity in hereditary hepatic porphyria. In: Richens A, Woodford FP (eds) Anticonvulsant drugs and enzyme induction, p. 137– 145. Elsevier, AmsterdamGoogle Scholar
  132. 132.
    McCarthy LJ, Aguilar JC, Ransburg R (1979) Fatal benign phenytoin lymphadenopathy. Arch Intern Med 139:367–368PubMedCrossRefGoogle Scholar
  133. 133.
    Merritt HH, Putnam TJ (1938) Sodium diphenyl hydantoinate in treatment of convulsive disorders. JAMA 111:1068–1073CrossRefGoogle Scholar
  134. 134.
    Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M (1963) Propriétés pharmacodynamiques de l’acide n-dipropylacétique. I. Propriétés antiépileptiques. Thérapie 18:435– 438PubMedGoogle Scholar
  135. 135.
    Meyer UA (1983) Porphyrie. In: Hadorn W, Stucki P, Hess T (Hrsg) Lehrbuch der Therapie, 7. Aufl, p. 513–515. Huber, Bern-Stuttgart-WienGoogle Scholar
  136. 136.
    Meyer UA (1985) Panhämatin. Persönliche Mitteilung aufgrund eines internen Merkblattes der Porphyriesprechstunde des Kantonsspitals BaselGoogle Scholar
  137. 137.
    Meyer-Wahl L (1980) Folsäuremangel als Mitursache für Kleinhirnatrophien bei antiepileptischer Langzeitmedikation. Nervenarzt 51:619–622PubMedGoogle Scholar
  138. 138.
    Milonas J, Kountouris D, Scheer E (1983) Myasthenisches Syndrom nach langzeitiger Diphenylhydantoin-Therapie. Nervenarzt 54:437–438PubMedGoogle Scholar
  139. 139.
    Nandedkar AK, Williamson R, Kutt H, Fairclough GF Jr (1980) A comparison of plasma phenytoin level determinations by EMIT and gas-liquid chromatography in patients with renal insufficiency. Ther Drug Monit 2:427–430PubMedGoogle Scholar
  140. 140.
    Nau H, Rating D, Koch S, Häuser I, Helge H (1981) Valproic acid and its metabolites: Placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219:768ä777PubMedGoogle Scholar
  141. 141.
    Nau H, Kuhnz W, Egger HJ, Rating D, Helge H (1982) Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 7:508–543PubMedCrossRefGoogle Scholar
  142. 142.
    Niebyl JR, Blake DA, Freeman JM, Luff RP (1979) Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 53:139–140PubMedGoogle Scholar
  143. 143.
    Niedermeyer E (1984) Awakening epilepsy („Aufwach-Epilepsie“) revisited 30 Years later. In: Degen R, Niedermeyer E (eds) Epilepsy, Sleep and Sleep Deprivation, p. 85–94. Elsevier, Amsterdam-New York-OxfordGoogle Scholar
  144. 144.
    Opitz A (1982) Zerebrale Krampfanfälle und Hypnoanalgetika. In: Opitz A, Degen R, Kugler J (Hrsg) Anästhesie bei Epileptikern und Behandlung des Status epilepticus, p. 39– 46. Editiones „Roches“ 1982Google Scholar
  145. 145.
    Orme M (1983) Oral contraceptives and anticonvulsant drugs. In: Jeavons PM, Anfield L (eds) Third International Symposium on Sodium Valproate. Br J Clin Pract, Symp Suppl 27:26–30Google Scholar
  146. 146.
    Parker PH, Helinek GL, Ghishan FK, Greene HL (1981) Recurrent pancreatitis induced by valproic acid. A case report and review of the literature. Gastroenterology 80:826–828PubMedGoogle Scholar
  147. 147.
    Perry-Keene DA, Larkins RG, Heyma P, Peter CT, Ross D, Sloman JG (1980) The effect of long-term diphenylhydantoin therapy on glucose tolerance and insulin secretion: A controlled trial. Clin Endocrinol (Oxford) 12:575–580CrossRefGoogle Scholar
  148. 148.
    Perucca E, Richens A (1981) Drugs interactions with phenytoin. Drugs 21:120–137PubMedCrossRefGoogle Scholar
  149. 149.
    Plochl E (1983) Leberkoma mit letalem Ausgang bei zwei Kindern unter antiepileptischer Dauertherapie. Padiatr Padol 18:57–63PubMedGoogle Scholar
  150. 150.
    Prichard JW (1980) Phenobarbital: Introduction. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neuroloy, Vol.27: p. 473–491. Raven Press, New YorkGoogle Scholar
  151. 151.
    Prichard JW (1980) Phenobarbital: Proposed mechanisms of antiepileptic action. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol. 27: p. 553–562. Raven Press, New YorkGoogle Scholar
  152. 152.
    Pynnönen S, Sillanpää M (1975) Carbamazepine and mother’s milk. Lancet II/563CrossRefGoogle Scholar
  153. 153.
    Rassmussen T (1975) Surgery of frontal lobe epilepsy. In: Purpura DP, Penry JK, Walter RD (eds) Neurosurgical Management of the Epilepsies, p. 197–205. Advances in Neurology, Vol 8. Raven Press, New YorkGoogle Scholar
  154. 154.
    Rassmussen T (1983) Hemispherectomy for seizures revisited. Can J Neurol Sci 10:71–78Google Scholar
  155. 155.
    Rating D (1985) Zum Mißbildungsrisiko einer Antiepileptika-Therapie in der Schwanger-schaft. Schweiz Rundschau Med (Praxis) 74:655–659Google Scholar
  156. 156.
    Rating D, Nau H, Kuhnz W, Jäger-Roman E, Helge H (1983) Antiepileptika in der Neugeborenenperiode. Monatschr Kinderheilk 131:6–12Google Scholar
  157. 157.
    Rawson MB (1968) Diphenylhydantoin intoxication and cerebrospinal fluid protein. Neurology 18:1009–1011PubMedGoogle Scholar
  158. 158.
    Reith H, Schäfer H (1979) Antiepileptika während Schwangerschaft und Stillzeit. Dtsch med Wschr 104:818–823PubMedCrossRefGoogle Scholar
  159. 159.
    Reynolds NC Jr (1982) Seizure management and hepatic porphyrias. Letter to the editor. Neurology 32:1409–1410PubMedGoogle Scholar
  160. 160.
    Reynolds NC Jr, Miska RM (1981) Safety of anticonvulsants in hepatic porphyrias. Neurology 31:480–484PubMedGoogle Scholar
  161. 161.
    Richens A (1976) Liver enzyme induction by antiepileptic drugs: Its clinical significance. In: Richens A, Woodford FP (eds) Anticonvulsant Drugs and Enzym Induction, p. 3–12. Elsevier, AmsterdamGoogle Scholar
  162. 162.
    Robert E, Guibaud P (1982) Maternal valproic acid and congenital neural tube defects. Lancet II/937CrossRefGoogle Scholar
  163. 163.
    Rossi L, Bonuccelli U, Maracacci G, Bindi A, De Scisciolo G, Arena R (1983) Gynecomastia in epileptics treatment with phenobarbital, phenytoin and fluoresone: two case reports. Ital J Neurol Sci 4:207–210PubMedCrossRefGoogle Scholar
  164. 164.
    Sandyk R (1983) Transient hemiparesis - a rare complication of phenytoin-toxicity. Postgrad Med J 59:601–602PubMedCrossRefGoogle Scholar
  165. 165.
    Schmidt D (1982) The effect of Pregnancy of the natural history of epilepsy: Review of the literature. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 3–14. Raven Press, New YorkGoogle Scholar
  166. 166.
    Schmidt D (1984) Behandlung der Epilepsien, 2. Aufl. Thieme, Stuttgart-New YorkGoogle Scholar
  167. 167.
    Schmidt D (1984) Adverse effects of Valproate. Epilepsia 25 (Suppl. 1):44–49CrossRefGoogle Scholar
  168. 168.
    Schmidt D, Vogel A (1977) Plasmakonzentrationen nach Injektion und Infusion von Phenytoin. Klin Wschr 55:219–223PubMedCrossRefGoogle Scholar
  169. 169.
    Schmidt D, Canger R, Avanzini G, Battino D, Cusi C, Beck-Mannagetta G, Koch S, Rating D, Janz D (1983) Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiat 46:751–755PubMedCrossRefGoogle Scholar
  170. 170.
    Schneble H (1981) SGPT und Gamma-GT bei Patienten mit antikonvulsiver Therapie unter besonderer Berücksichtigung der Serumkonzentrationen der Antiepileptika. Med Welt 32:427–431PubMedGoogle Scholar
  171. 171.
    Schwartau M, Wahl G, Bucking J (1983) Intramyokardialer Block bei Carbamazepin-In-toxikation. Dtsch Med Wschr 108:1841–1843PubMedCrossRefGoogle Scholar
  172. 172.
    Schweingruber R (1980) Die Barbiturate. Schweiz Rundschau Med (Praxis) 69:790–794Google Scholar
  173. 173.
    Selhorst JB, Kaufman B, Horwitz SJ (1972) Diphenylhydantoin induced cerebellar degeneration. Arch Neurol (Chicago) 27:453–455CrossRefGoogle Scholar
  174. 174.
    Serrano EE, Roye DB, Hammer RH, Wilder BJ (1973) Plasma diphenylhydantoin values after oral and intramuscular administration of diphenylhydantoin. Neurology 23:311–317PubMedGoogle Scholar
  175. 175.
    Serrano EE, Wilder BJ (1974) Intramuscular administration of diphenylhydantoin. Arch Neurol 31:276–278PubMedCrossRefGoogle Scholar
  176. 176.
    Sheridan WP, King RW, Gerstman M (1982) Fever as an adverse reaction to carbamazepine. Aust NZJ Med 12:520–522CrossRefGoogle Scholar
  177. 177.
    Shervin AL, Robb JP (1972) Ethosuximide. Relation of plasma level to clinical control (continued). In: Woodbury DM, Penry JK, Schmidt RP (eds) Antiepileptic Drugs, p. 443– 448. Raven Press, New YorkGoogle Scholar
  178. 178.
    Sidiropoulos D (1982) Pränatale Diagnostik von angeborenen Anomalien. Pädiat Fort-bildk Praxis Bd 53, p. 128–145. Karger, BaselGoogle Scholar
  179. 179.
    Simila S, Wendt von L., Linna SL (1980) Dipropylacetate and aminoaciduria. J Neurol Sci 45:83–86PubMedCrossRefGoogle Scholar
  180. 180.
    Sonnen AEH (1980) Hormonelle Kontrazeption, antikonvulsive Therapie und Epilepsie-verlauf. In: Doose H et al (Hrsg) Epilepsie 1979. Ehe, Schwangerschaft, Geburt, genetische Beratung, p. 86–94. Thieme, Stuttgart-New YorkGoogle Scholar
  181. 181.
    Srinivasan G, Seeler RA, Tiruvury A, Pildes RS (1982) Maternal anticonvulsant therapy and hemorrhagic disease of the newborn. Obstet Gynecol 59:250–252PubMedGoogle Scholar
  182. 182.
    Stempel LE, Moore TD (1982) Anticonvulsant therapy during pregnancy. In: Rayburn WF, Zuspan FP (eds) Drug Therapy in Obstetrics and Gynecology, p. 43–64. Rayburn, Norwalk Appelton-Century-CroftsGoogle Scholar
  183. 183.
    Sullivan JB Jr, Rumack BH, Peterson RG (1981) Acute carbamazepine toxicity resulting from overdose. Neurology 31:621–624PubMedGoogle Scholar
  184. 184.
    Suria A, Killam EK (1980) Carbamazepine. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol.27: p. 563–575. Raven Press, New YorkGoogle Scholar
  185. 185.
    Swift TR, Gross JA, Ward LC, Crout BO (1981) Peripheral neuropathy in epileptic patients. Neurology 31:826–831PubMedGoogle Scholar
  186. 186.
    Taylor RL (1981) Magnesium sulfate for AIP seizures. Neurology 31:1371–1372PubMedGoogle Scholar
  187. 187.
    Teramo K, Hiilesmaa V, Bardy A, Saarikoski S (1979) Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 7:3–6PubMedCrossRefGoogle Scholar
  188. 188.
    Teramo K, Hiilesmaa VK (1982) Pregnancy and fetal complications in epileptic pregnancies: Review of the literature. In: Janz D et al (eds) Epilepsy, Pregnancy and the Child, p. 53–59. Raven Press, New YorkGoogle Scholar
  189. 189.
    Tomsick RS (1983) The phenytoin syndrome. Cutis 32:535–541PubMedGoogle Scholar
  190. 190.
    Van der Starre P (1980) Etomidat als schnellwirkende antiepileptische Substanz. In: Opitz A, Degen R (Hrsg) Anästhesie bei zerebralen Krampfanfällen und Intensivtherapie des Status epilepticus, p. 205–208. Perimed-Fachbuch-Verlagsgesellschaft, ErlangenGoogle Scholar
  191. 191.
    Van Wieringen A, Vrijland CM (1983) Ethosuximide intoxication caused by interaction with isoniazid. Neurology 33:1227–1228PubMedGoogle Scholar
  192. 192.
    Vassella F (1977) Gelegenheitskrämpfe. Schweiz Rundschau Med (Praxis) 66:1331–1337Google Scholar
  193. 193.
    Vassella F (1982) Phenytoin (DPH) in der Padiatrie. Sozialpädiatrie in Praxis u. Klinik 4:87–90Google Scholar
  194. 194.
    Vassella F (1984) Medikamentöse Behandlung der Epilepsie. In: Berner Datenbuch der Pädiatrie, p. 558–565. Fischer, Stuttgart-New YorkGoogle Scholar
  195. 195.
    Vassella F, Pfenninger J (1975) Chemotherapie der Infektionskrankheiten im Säuglings-und Kindesalter. Schweiz med Wschr 105:263–266PubMedGoogle Scholar
  196. 196.
    Vossen R (1958) Über die antikonvulsive Wirkung von Succinimiden. Dtsch med Wschr 83:1227–1230PubMedCrossRefGoogle Scholar
  197. 197.
    Ware S, Millward-Sadler GH (1980) Acute liver disease associated with sodium valproate. Lancet II/1110–1113CrossRefGoogle Scholar
  198. 198.
    Warter JM, Brandt C, Maresceaux C, Rumbach L, Micheletti G, Chabrier G, Krieger J, Imler M (1983) The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology 33:1136–1140PubMedGoogle Scholar
  199. 199.
    Warter JM, Imler M, Marescaux C, Chabrier G, Rumbach L, Micheletti G, Krieger J (1983) Sodium valproate-induced hyperammonemia in the rat. Role of the kidney. Eur J Pharmacol 87:177–182PubMedCrossRefGoogle Scholar
  200. 200.
    Watson DL, Sibai BM, Shaver DC, Dacus JV, Anderson GD (1983) Late postpartum eclampsia: An update. South Med J 76:1487–1489PubMedCrossRefGoogle Scholar
  201. 201.
    Wauquier A (1983) Profil of etomidate. A hypnotic, anticonvulsant and brain protective compound. Anaesthesia 38 (Suppl):26–33PubMedCrossRefGoogle Scholar
  202. 202.
    Wieser HG (1985) Derzeitige Möglichkeiten der operativen Epilepsiebehandlung. Nervenarzt 56: Im DruckGoogle Scholar
  203. 203.
    Wieser HG, Yasargil MG (1982) Die „selektive Amygdala-Hippokampektomie“ als chirurgische Behandlungsmethode der mediobasal-limbischen Epilepsie. Neurochirurgie 25:39– 50Google Scholar
  204. 204.
    Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ (1983) Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 33:1474–1476PubMedGoogle Scholar
  205. 205.
    Wilensky AJ, Lowden JA (1973) Inadequate serum levels after intramuscular administration of diphenylhydantoin. Neurology 23:318–324PubMedGoogle Scholar
  206. 206.
    Wolf P, Inoue Y, Räder-Wanner UU, Tsai JJ (1984) Psychiatric complications of absence therapy and their relation to alteration of sleep. Epilepsia 25:556–559CrossRefGoogle Scholar
  207. 207.
    Woodbury DM (1972) Bromides. In: Woodbury DM, Penry JK, Schmidt RP (eds) Anti-epileptic Drugs, p. 519–527. Raven Press, New YorkGoogle Scholar
  208. 208.
    Woodbury DM (1980) Phenytoin: Proposed mechanisms of anticonvulsant action. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanisms of Action. Advances in Neurology, Vol 27:447–471. Raven Press, New YorkGoogle Scholar
  209. 209.
    Yeung Laiwah AAC, Rapeport WG, Thomson GG, Macphee GJA, Philip MF, Moore MR, Brodie MJ, Goldberg A (1983) Carbamazepine-induced non-hereditary porphyria. Lancet I/790–793CrossRefGoogle Scholar
  210. 210.
    Zackai EH, Mellman WJ, Neiderer B, Hanson JW (1975) The fetal trimethadione syndrome. J Pediatr 87:280–284PubMedCrossRefGoogle Scholar
  211. 211.
    Zimmerman FT, Burgemeister BB (1958) A new drug for petit mal epilepsy. Neurology 8:769–775PubMedGoogle Scholar
  212. 212.
    Zysset T, Bircher J (1980) Verbesserte Dosierung von Antiepileptika mit Hilfe von Konzentrationsmessungen im Plasma. Schweiz Rundschau Med (Praxis) 69:835–839Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • Kazimierz Karbowski
    • 1
  1. 1.Chefarzt an der Neurologischen Universitätsklinik, InselspitalBernSwitzerland

Personalised recommendations